

Micromedex

product detailing

2019



KIMS Co.,Ltd.
Ken Kwon
+82-2-3019-9335
kukwon@kims.co.kr

1. What is “Micromedex”?
2. Why is “Micromedex”?
3. Micromedex Tools
4. Micromedex Search Skill
5. Micromedex 활용
6. Mobile Micromedex
7. Appendix

1. What is “Micromedex”?

MICROMEDEX

evidence-based clinical reference

- Clinical decision support tool
- Drug information database

Introducing Micromedex



- MICROMEDEX®는 의약, 질병, 환경, 독성 등 임상 현장에서 필요로 하는 모든 정보로 구성된 전문 임상약학 Database로서 전세계 92개국, 국내 약 80여 곳의 병원, 제약회사, R&D 센터, 정부기관, 산업현장에서 이용 중이며 특히 병원의 경우, 국내 대형 병원에서 대부분 MICROMEDEX®를 이용하고 있는 대표적인 전문임상약학Database 입니다.
- 전문가들에 의해 철저히 검증된 의약품 모노그래프와 상담자료로서 전 세계 처방 및 비처방(OTC)의약품의 용법/용량, 약물동력학, 주의사항 (부작용, 금기, 임부/수유부 안전성 등), 상호작용 (약물-약물, 음식, 질병, 담배/술 등), 임상적용, 비교유효성 등의 정보를 제공하고 있습니다.
- 1977년 미국의회로부터 Official Drug Compendium 로 인정받았습니다.
- Micromedex editorial process는 NICE 인증을 받았습니다.

Micromedex Product



MICROMEDEX Product Information

제품군	제품명	설명
의약품 정보 Drug Knowledge	DRUGDEX	전문가들에 의해 철저하게 검증된 의약품 모노그래프와 상담자료로서 전 세계 처방 및 비처방 (OTC)의약품의 용법/용량, 약물동력학, 주의사항 (부작용, 금기, 임부/수유부 안전성 등), 상호작용 (약물-약물, 음식, 질병, 담배/술 등), 임상적용, 비교유효성 등의 정보를 제공 1,900여성분, 150,000제품정보 수록하고 있으며 모노그래프 분량은 20~350 page 1977년 미국의회로부터 Official Drug Compendium 로 인정
	Complete DRUG Interactions	약물-약물, 약물-음식, 약물-질병, 약물-알코올, 약물-담배 및 실험실정보에 대한 상호작용 정보 제공.
	Complete IV Compatibility	약물과 용제 정보 (600여종), Y사이트 위치, 혼합 및 안정성, 농도정보 등의 주사제 배합정보 제공
	MARTINDALE	미국, 영국 및 전 세계적으로 사용되는 의약품의 일반명 및 제품명, 동의어 및 화학명, 분자식, 분자량, CAS number, 물리적 특성, 사용금기 및 사용상 주의, 상호작용, 약물동력학, 약리학을 비롯한 용법/용량 정보 등 70,000여 제품 5,000여 성분에 대한 정보 제공
	AltMedDex	전문인용 민간요법 상세정보 Database로서 대체약 및 보조식품에 대한 증거중심의 (evidence-based) 신뢰성 있는 정보
	AltMedDex Protocols	질병별 민간요법, 식이요법, 건강보조식품 정보를 통합하여 제공하는 전문인용 대체요법 질병 치료 프로토콜
	Neofax	신생아 의약품 정보

Micromedex Product



제품군	제품명	설명
질환정보 Disease Management	DISEASEDEX General Medicine	일반질환의 임상정보, 검사정보, 증상 및 감별진단, 치료 등의 상세 정보로써 입원/외래 환자 진료시의 의학적인 증거를 제시하고, 최선의 진단, 치료 방법을 제공.
	DISEASEDEX Emergency Medicine	응급시 질병 별 임상정보, 검사정보, 증상 및 감별진단, 치료 등의 상세 정보로써 진단과 치료 방법에 대해 응급의학 임상의 들이 기술.
	Lab Advisor	적합한 시험검사를 확인하고 해석하기 위한 정보. 검사결과에 영향을 미치는 약물 정보 등.
독성정보 Toxicology Knowledge	POISINDEX	1,000 treatment protocols 이 수록된 세계 최고의 독성관리 참고서로써 1백만여종 이상의 가정용품, 의약품, 산업 및 환경, 생물학적 물질등의 독성정보 제공. 치료 protocols, 중독증상 및 임상증상, 독성범위 (Range of toxicity) 등 정보 제공. US 의회에서 Official Poison Compendium 으로 인증
	REPRORISK	세계최고의 정확하고 상세한 의약품, 화학물질, 화재, 소음 및 환경으로 인한 생식계 위험도 정보, 4개의 DB로 구성 - TERIS (University of Washington): 분류등급에 따른 의약품 및 환경물질의 초기형성도 (embryo malformation) - REPROTEXT (Micromedex): 화학물질, 열, 방사선조사 및 소음에 의한 Reproductive, carcinogenic & genetic effects - REPROTOX (Reproductive Toxicology Center): 방사선조사, 식품첨가물, 기타 의약품 등의 수태능력, 남성의 생식능력, 수유등에 미치는 독성정보 - Shepard's Catalog of Teratogenic agents (Dr. T Shepard): 식품첨가물, 가정용품, 환경오염물질 및 바이러스 등에 의한 생식독성정보
	TOMES Plus	HAZARDTEXT, INFOTEXT, MEDITEXT. 산업 및 작업환경에서 화학제품 취급/처리시 정보. 노출, 유출, 폭발 등의 정보.
환자교육자료 Patient Education	CareNotes	전 세계 15개국 언어로 번역되어 있는 약물복용, 질병, 검사정보 등에 관련된 환자용 교육 자료.
	AltCareDex	자가요법, 한약(허브) 및 식이요법/건강보조식품에 대한 정보를 요약하여, 환자 상담시에 활용하도록 함. 케어노트 형식의 환자 교육 자료
	Consumer Health Solution	환자와 일반인에게 제공하는 다양한 건강정보와 질병정보로 이루어져 있으며 멀티미디어나 애니메이션을 활용하여 환자에게 보다 쉽게 정보제공이 가능, 맞춤형 솔루션 제작 가능


Evidence-based editorial content
has been thoroughly reviewed by our experts

90+ editorial staff members(full days)


7,000+ journals researched

500,000+ articles reviewed annually

Editorial Process



TRIAGE AND REVIEW
BY SENIOR CLINICIANS



APPLY LITERATURE
INCLUSION/EXCLUSION
CRITERIA



SENIOR CLINICIANS
SELECT LITERATURE
FOR CONTENT



Literature Evaluation

- Rigorous Literature Evaluation Policy
 - Evaluation of the quality of the study so that only the best evidence is incorporated into Micromedex content
 - Determination of clinical significance of the study drives update prioritization
- Conflict of Interest Policy to protect against outside influence

We include the best of the available medical literature in our content



ALERTS FROM FDA AND
MEDICAL
ORGANIZATIONS



AUTOMATED
LITERATURE
SURVEILLANCE



TARGETED
SEARCHES BY
MEDICAL LIBRARIANS

Literature Surveillance

Our Knowledge Development staff monitor the worlds medical literature every day

- Estimated over 12,000 medical articles published per week
 - On-going literature surveillance
 - Primary literature
 - Regulatory bodies
 - Guideline organizations
 - Targeted Searches
 - Specific topics
 - Clinical specialty
- Frequency of surveillance is driven by the topic
- Significant annual investment in library resources

Identification of the full body of evidence on a topic is essential to provide fully informed recommendations



Official Accreditation

- The National Institute of Health and Care Excellence (NICE) has accredited the process used by IBM Watson Health to develop content used in its MICROMEDEX Solutions.
- For full details on our accreditation visit: www.nice.org.uk/accreditation

2. Why is “Micromedex”?

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes®	NeoFax® / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	------------	----------------------	---------------

Rivaroxaban

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: [Oral](#)

Quick Answers	In-Depth Answers	All Results
---------------	------------------	-------------

Related Results

[Alternative Medicine](#)
[Disease](#)
[Toxicology](#)

[Consumer Drug Information](#)
[Drug Consults](#)
[eMC SmPC \(UK\)](#)
[Index Nominum](#)
[IT- Dialogo Sui Farmaci](#)
[Martindale](#)
[PDR®](#)
[Product Lookup - Martindale](#)
[Product Lookup - RED Book Online](#)
[Product Lookup - Tox & Drug](#)

Filter by

[All \(376\)](#)
[Drug \(355\)](#)
[Disease \(14\)](#)
[Toxicology \(2\)](#)
[Alternative Medicine \(3\)](#)
[Reproductive Risk \(2\)](#)

1-15 of 376 Results for "Rivaroxaban"

RIVAROXBAN

Drug: Detailed evidence-based information

Rivaroxaban

Oral

Drug: Summary topic

XARELTO 5 cpr riv 10 mg

Farmaco: Sintesi delle Informazioni del Prodotto (*Dialogo sui Farmaci*)

XARELTO 10 cpr riv 10 mg

Farmaco: Sintesi delle Informazioni del Prodotto (*Dialogo sui Farmaci*)

XARELTO 30 cpr riv 10 mg

Farmaco: Sintesi delle Informazioni del Prodotto (*Dialogo sui Farmaci*)

XARELTO 100 cpr riv 10 mg

Farmaco: Sintesi delle Informazioni del Prodotto (*Dialogo sui Farmaci*)

XARELTO 42 cpr riv 15 mg

Farmaco: Sintesi delle Informazioni del Prodotto (*Dialogo sui Farmaci*)

XARELTO 28 cpr riv 20 mg

Farmaco: Sintesi delle Informazioni del Prodotto (*Dialogo sui Farmaci*)

Xarelto 15mg film-coated tablets

Drug: Summary of Product Characteristics (eMC)

Xarelto 20mg film-coated tablets

Drug: Summary of Product Characteristics (eMC)

Xarelto 10 mg film-coated tablets

Drug: Summary of Product Characteristics (eMC)


ENTERAL FEEDING TUBES AND MEDICATION DELIVERY

Drugdex® 콘텐츠 정보

- 약물,약품 의약품 약동학 및 약품 정보
- 약물비교 정보
- 약물상호 작용
- 약품식별 정보
- 부작용,금기,임부 안전성 정보
- 주사제 배합 정보
- TPN, TNA 정보
- 신생아 의약품 정보
- FDA 승인약품 상세 정보
- Non-FDA 약품 임상 정보
- 독성 정보
- 생식독성 정보
- 질병,질환 임상 정보
- 화학제품 취급/처리 정보
- 환자교육 정보

② Martindale

- 전세계적으로 공신력 있게 사용되고 있는 Martindale DB 제공
- Martindale은 치료약물, 임상시험약물, 약용식물, 진단시약, 살충제, 염색약, 방부제, 유해물질에 대한 정보를 포괄



Home Drug Interactions IV Compatibility Drug ID Drug Comparison CareNotes® NeoFax® / Pediatrics Other Tools ▾

Rivaroxaban

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: Oral

Quick Answers In-Depth Answers All Results

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS
- Drug Interactions (single)
- IV Compatibility (single)

Toxicology

Treatment

RIVAROXABAN AND RELATED AGENTS

- Support: MILD TO MODERATE TOXICITY: Treatment is symptomatic and supportive. Transfusion of packed red cells and fresh plasma may be required in severe cases.
- Decontamination: PREHOSPITAL: Consider activated charcoal after a recent potentially toxic ingestion and if the patient is able to maintain their airway or if the airway is protected. HOSPITAL: Consider activated charcoal after a recent potentially toxic ingestion and if the patient is able to maintain their airway or if the airway is protected.
- Airway management: Assess airway; endotracheal intubation may be required in patients with intracranial bleeding or severe hemoptysis or upper GI bleeding.
- Antidote: None.
- Monitoring of patient: Monitor for evidence of bleeding (eg, venous access sites, urinary, gastrointestinal, vaginal). Monitor serial hemoglobin and hematocrit in patients with suspected bleeding. Monitor CBC with platelet count, vital signs, and liver enzymes in symptomatic patients. Prothrombin time (PT) and aPTT are relatively insensitive in measuring the activity of rivaroxaban at therapeutic doses, but may be prolonged after overdose. Plasma anti-factor Xa concentrations can be measured, but results are generally not available rapidly enough to use this to guide therapy.
- Enhanced elimination procedure: Rivaroxaban is highly protein bound and dialysis is not expected to adequately to be useful after overdose.
- Patient disposition: HOME MANAGEMENT: Patients that unintentionally ingest one or two doses of oral rivaroxaban may be observed at home. OBSERVATION CRITERIA: Intentional overdoses and patients with bleeding complications should be referred to a healthcare facility. Patients with minor bleeding complications can be observed until the bleeding is controlled. ADMISSION CRITERIA: Patients with more than minor bleeding complications should be admitted for serial hemoglobin and hematocrit monitoring. CONSULT CRITERIA: If the patient still requires anticoagulation, hematology should be consulted for anticoagulation guidance. A toxicologist or poison center should be consulted in patients with severe toxicity.

Martindale

- [Cardiovascular Drugs](#)
- [Rivaroxaban](#)


Print Close

Related Results

- Alternative Medicine
- Disease
- Toxicology
- Consumer Drug Information
- Drug Consults
- eMC SmPC (UK)
- Index Nominum
- IT - Dialogo S.r.l. Farmaci
- Martindale**
- PDR®
- Product Lookup - Martindale
- Product Lookup - RED Book Online
- Product Lookup - Tox & Drug

③ PDR

- PDR은 미국 FDA 승인된 2,800종 이상의 의약품의 허가정보를 수록
- PDR, 일반의약품 및 영양보충제 PDR, 안과 약물 PDR 수록



The screenshot shows the PDR website interface for Rivaroxaban. The top navigation bar includes links for Home, Drug Interactions, IV Compatibility, Drug ID, Drug Comparison, CareNotes®, NeoFax® / Pediatrics, and Other Tools. The main content area is titled "Rivaroxaban" and lists drug classes (Anticoagulant, Blood Modifier Agent) and routes (Oral). A sidebar on the left contains navigation tabs for Dosing/Administration, Medication Safety, and Toxicology. The Toxicology section is active, showing "RIVAROXABAN AND RELATED AGENTS" with a list of clinical considerations. A popup window titled "PDR@" is overlaid on the page, displaying a search result for "Xarelto" and buttons for "Print" and "Close". On the right side, there is a "Related Results" section with various links, including "PDR@" which is highlighted with a red box.

④ Drug Consults

- Micromedex Editorial Team에서 자체 제작한 질병, 약물 등에 대한 다양한 주제를 다룬 자료 제공
- 임상 가이드라인, 비교 테이블을 포함

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	C
------	-------------------	------------------	---------	-----------------	---

Drug Consults

Jump To: [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#)

Displaying 45 of 465 "Drug Consults"

Abbreviations

ABVD - USED FOR HODGKIN'S DISEASE

AC - USED FOR BREAST CANCER

AC - USED FOR MULTIPLE MYELOMA

AC FOLLOWED BY T WITH TRASTUZUMAB - USED FOR BREAST CANCER

ACE INHIBITOR-INDUCED ACUTE RENAL FAILURE

ACE INHIBITOR-INDUCED ANGIOEDEMA

ACE INHIBITOR-INDUCED COUGH

ACE INHIBITOR-INDUCED COUGH

약물 자문

RESPONSE

- INCIDENCE
 - Frequent (incidence 1% or greater)
 - The incidence of ACE inhibitor-induced cough has been estimated at 0.7% to 48%, in a review of literature from the 1980s [1]. Later postmarketing surveys reported an incidence rate of between 0% to 12%, while specifically designed prospective studies of cough reported an incidence between 7% to 15% within the general population [2][3][4][5]. A prospective study of 100 Nigerians revealed a 27% incidence, with a 3:1 female-preponderance [6]. During trials with quinapril among nearly 6000 patients, spontaneous reporting of cough occurred in 2.7% [7][8]; when then queried by standard questionnaire for adverse effects, the percentage of patients reporting cough increased to 13.5% [7].
 - Representative comparative ranges of incidence of cough and withdrawal rates in patients without regard to specific high-risk factors include:

Drug	Incidence	Withdrawal	Reference
Benzazepril	1.2%		1
Captopril	0.5-2%		24
Captopril	0.5-2%		24
Cilazapril	3.2%		22
Delapril	12.3%	4%	2
Enalapril		10%	23
Fosinopril	2-10%		3-4
Lisinopril	3.5%		5-6
Moexipril	8%	1%	7-8
Prenidopril	7-12%	1-3%	9-10
Quinapril	14%		11-13
Ramipril	3-12%	4%	14-15
Spirapril	0.9-4%		16-18, 21
Trandolapril	3-4%	0.1%	19-20

ACE INHIBITOR-INDUCED COUGH

약물 자문

CLINICAL MANAGEMENT

- PROPHYLACTIC MEASURES:
 - A careful differential diagnosis may prevent unnecessary interruption of ACE inhibitor treatment and should include consideration of the following: postnasal drip, asthma, upper respiratory tract infection, heart failure, gastroesophageal reflux disease, and smoking [10].
- PHARMACOLOGIC:
 - A 4-day trial withdrawal of the ACE inhibitor and/or substitution of another class of antihypertensive is considered the most effective and least expensive method of determining whether cough is indeed drug-induced and proceeding with treatment if it is.
 - In a trial involving patients with known enalapril-induced cough, rechallenge with enalapril led to recurrence in approximately 44%, while treatment with eprosartan led to cough in 20%, a rate similar to those treated with placebo. In 84 elderly patients with cough induced by previous ACE inhibitor therapy and confirmed during rechallenge with lisinopril 10 mg daily, double-blind challenge with either losartan 50 mg daily or metolazone 1 mg daily resulted in recurrence in 18% to 21% of patients [21]. Two elderly women had recurrent cough develop 2 weeks after losartan was substituted for lisinopril [27].
 - An alternative ACE inhibitor is generally not considered a viable alternative, since cross-reactivity is likely to occur.
 - Eight of 24 patients who received fosinopril as an alternative to other ACE inhibitor therapy cleared completely [14][13], while another 24 patients who were switched to fosinopril after developing cough on other ACE inhibitors reported subjective improvement in such cough characteristics as frequency, severity, effects on sleep, and mucus production [15].
 - Daily supplementation with 50 mg elemental iron (as ferrous sulfate 265 mg) reduced subjective cough within 4 weeks in 8 of 10 patients, completely resolving cough in 3 [28].
 - Antitussive therapy is generally ineffective for true ACE inhibitor-induced cough [1].
 - Sulindac 100 mg orally twice daily and diclofenac have also been effective in treating cough secondary to ACE inhibitors in limited studies [16]. However, NSAIDs may interfere with the hypotensive action of ACE inhibitors and cannot be enthusiastically recommended [29].
 - Bupivacaine aerosol (3 mL of a 0.5% solution) has been effective in terminating captopril-induced cough and controlling the cough for 5 to 6 weeks following treatment. However, the use of topical anesthetics are not generally recommended due to loss of the swallowing reflex (for 4 hours) and the possibility of bronchospasm [16].
 - Cromolyn sodium inhalation was claimed to completely resolve coughing in 3 of 6 patients, with improvement in another 2; dose and duration of therapy were unspecified [30]. However, since cromolyn may also induce similar adverse effects (ie, cough, wheezing, bronchospasm), its use is not encouraged [29].
 - Both theophylline and nifedipine are cited as additional agents that have been explored for potential benefit in treating ACE inhibitor-associated cough, but either have no proven efficacy or, in the case of nifedipine, have potential negative inotropic effects which would preclude its use in patients with heart failure. As with all other suggested alternatives, the value of adding yet another drug which carries either its own unique adverse effects or the potential for inducing drug-drug interactions into an existing regimen must be questioned [10].
- NON-PHARMACOLOGIC

처방 가이드라인 제공



- 전 세계에서 발표된 다양한 처방 기준도 포함하여 제공

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes®	NeoFax® / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	------------	----------------------	---------------

BEERS CRITERIA - A SUMMARY OF POTENTIALLY INAPPROPRIATE MEDICATION US...

약물 지문



↑ 페이지

RESPONSE

In 1991, Dr. Mark Beers and colleagues published criteria developed by consensus and literature methodology identifying inappropriate medication use among institutionalized elderly patients. Since 1991, these criteria have been updated and revised and present the Beers criteria (Beers List) is one of the most widely cited criteria for inappropriate medication use in older adults aged 65 years or greater [1][2][3].

Inappropriate medication use refers to the use of medications that are either ineffective, or they pose an unnecessary risk of harm. The American Geriatrics Society (AGS) Beers criteria, the quality of supporting evidence, and quality of evidence ratings:

Strength of recommendation	Description
Strong	Benefits clearly outweigh risks (benefits)
Weak	Benefits finely balanced with risks
Insufficient	Not enough data

Quality of evidence	Description
High	Evidence from large, well-conducted

Reference

1. Beers MH, Ouslander JG, Rollingher I, et al: Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151(10):1116-1121.
PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>
PubMed Article: <http://www.ncbi.nlm.nih.gov/...>
2. Beers MH: Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997; 157(14):1531-1536.
PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>
PubMed Article: <http://www.ncbi.nlm.nih.gov/...>
3. Fick DM, Cooper JW, Wade WE, et al: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163(20):2716-2724.
PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>
PubMed Article: <http://www.ncbi.nlm.nih.gov/...>
4. American Geriatrics Society 2012 Beers Criteria Update Expert Panel: American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2012; 60(11):1619-1631.
PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>
PubMed Article: <http://www.ncbi.nlm.nih.gov/...>
5. Chutka DS, Takahashi PY, & Hoel RW: Inappropriate medications for elderly patients. Mayo Clin Proc 2004; 79(1):122-139.
PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>
PubMed Article: <http://www.ncbi.nlm.nih.gov/...>
6. Jano E & Aparasu RR: Healthcare outcomes associated with Beers' criteria: a systematic review. Ann Pharmacother 2007; 41(3):438-447.
PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>
PubMed Article: <http://www.ncbi.nlm.nih.gov/...>

Last Modified: July 01, 2014

적응증 정보



- 적응증에 관한 정보는 FDA 승인 적응증(FDA Uses)과 FDA 미승인 적응증(Non-FDA Uses)으로 분류하여 제공
- 적응증에 관한 정보를 요약정보와 상세정보로 나누어 제공
- 추천 등급(Class I/II/III)와 문헌 보고도(Category A/B/C) 제공

Rivaroxaban

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: Oral

Quick Answers

In-Depth Answers

All Results

Dosing/Administration

Adult Dosing

Pediatric Dosing

FDA Uses

Non-FDA Uses

Dose Adjustments

Administration

Comparative Efficacy

Place In Therapy

Medication Safety

Contraindications

Precautions

Adverse Effects

Black Box Warning

Dosing/Administration

Non-FDA Uses

See 'In-Depth Answers' for detailed results.

- Acute coronary syndrome, Recent - Cardiovascular event risk; Prophylaxis 
- Venous thromboembolism, In Acutely Ill Medical Patients; Prophylaxis 

Rivaroxaban

Acute coronary syndrome, Recent - Cardiovascular event risk; Prophylaxis

FDA Approval:

- Adult, no
- Pediatric, no

Efficacy:

- Adult, Evidence favors efficacy

Strength of Recommendation:

- Adult, [Class IIb](#)

Strength of Evidence:

- Adult, [Category B](#)

인쇄

닫기

약물 효능/효과 비교 정보



- **Comparative Efficacy:** 특정 적응증에 대한 약물 비교 자료 제공
- **Place In Therapy:** 해당 성분의 약물이 치료 과정에 있어 어떤 위치를 차지하고 있는지 분석한 자료 제공, Drug Consult 자료로 연결

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes®	NeoFax® / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	------------	----------------------	---------------

Glimepiride

Drug Classes: [2nd Generation Sulfonylurea](#) | [Antidiabetic](#) | [All](#)

Routes: [Oral](#)

Quick Answers	In-Depth Answers	All Results
---------------	------------------	-------------

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration

- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications

Dosing/Administration

Comparative Efficacy

- [Canagliflozin](#)
- [Empagliflozin](#)
- [Glyburide](#)
- [Linagliptin](#)
- [Liraglutide](#)
- [Metformin](#)
- [Pioglitazone](#)
- [Repaglinide](#)
- [Sitagliptin](#)
- [Vildagliptin](#)

Canagliflozin

Type 2 diabetes mellitus

a) In a 104-week randomized study (N=1450) canagliflozin provided larger reductions in HbA1C, weight loss, and less l

Glimepiride

Drug Classes: [2nd Generation Sulfonylurea](#) | [Antidiabetic](#) | [All](#)

Routes: **Oral**

- Quick Answers
- In-Depth Answers**
- All Results

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy**
- Place In Therapy

Dosing/Administration Comparative Efficacy

- Canagliflozin
- Empagliflozin
- Glyburide
- Linagliptin
- Liraglutide
- Metformin
- Pioglitazone
- Repaglinide
- Sitagliptin
- Vildagliptin

[View Full Document](#)
[Print](#)

Medication Safety

- Contraindications
- Precautions
- Adverse Effects

Canagliflozin

Type 2 diabetes mellitus

a) In a 104-week randomized study (N=1450), canagliflozin provided larger reductions in HbA1C, weight loss, and less hypoglycemia compared with glimepiride. The mean HbA1C reduction from baseline (baseline mean, 7.8%) at 104 weeks with canagliflozin 300 mg (-0.74%) was significantly larger compared with glimepiride (-0.55%), while the reduction with canagliflozin 100 mg (-0.65%) was similar to glimepiride. The lowest HbA1C values were reported after 52 weeks of treatment in the canagliflozin groups, and after 48 weeks in the glimepiride group. HbA1C increased for the rest of the study duration, but the increase was significantly lower in the canagliflozin groups. Both

Glimepiride

Drug Classes: [2nd Generation Sulfonylurea](#) | [Antidiabetic](#) | [All](#)

Routes: **Oral**

- Quick Answers
- In-Depth Answers**
- All Results

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy**
- Medication Safety

Dosing/Administration Place In Therapy

[View Full Document](#)
[Print](#)

A) Glimepiride is a sulfonylurea antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [50].
 B) In a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), a less prescriptive, patient-centered approach to the treatment of type 2 diabetes reflective of individual patient preferences, needs, and values is recommended over algorithmic approaches of past guidelines. Metformin therapy, if there are no specific contraindications and if tolerated, is recommended as the optimal first-line drug for treatment of type 2 diabetes mellitus. Following initiation of metformin, there is limited data to recommend a specific strategy for implementation of drug therapy, so agent- and patient-specific properties such as dosing frequency, side-effect profiles, cost, and other benefits may be used to guide therapy. Sulfonylureas may be used as initial treatment in cases where metformin cannot be used, and they may be administered as a component of combination therapy in patients unable to achieve HbA1c goals with lifestyle interventions and metformin monotherapy [3]. As with other antidiabetic drugs, no clinical studies have established conclusive evidence of macrovascular risk reduction with glimepiride [50].
 See Drug Consult reference: [DIABETES MELLITUS: GUIDELINES FOR DRUG THERAPY](#)

환자별 약물 용량 정보



- 성인 용량(Adult Dosing): 용법/용량 안에 기본적으로 성인 용량 정보 제공
- 소아 용량(Pediatric Dosing): 성인 용량과 구분하여 개별적 제공
- 특수 환자에 대한 용량 조절 정보(Dose Adjustments): 간장애, 신장애, 노인 용량 조절 주의가 필요한 특수 환자의 용량 조절 정보 제공

Home | Drug Interactions | IV Compatibility | Drug ID | Drug Comparison | CareNotes® | NeoFax® / Pediatrics | Other Tools ▼

Rivaroxaban

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: Oral

Quick Answers | In-Depth Answers | All Results

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS

Dosing/Administration

Dose Adjustments

See 'In-Depth Answers' for detailed results.

- renal impairment in nonvalvular atrial fibrillation, CrCl greater than 50 mL/min: 20 mg ORALLY once daily with the evening meal [5]
- renal impairment in nonvalvular atrial fibrillation, CrCl 15 to 50 mL/min: 15 mg ORALLY once daily with the evening meal [5]
- renal impairment in nonvalvular atrial fibrillation, CrCl less than 15 mL/min: Avoid use [5]
- renal impairment in postoperative prophylaxis of DVT and treatment and prevention of recurrent DVT/pulmonary embolism, CrCl less than 30 mL/min: Avoid use [2]
- renal impairment, acute renal failure: Discontinuation recommended [5]
- renal impairment, CrCl 15 to 80 mL/min: Avoid concomitant use with drugs that are both P-glycoprotein inhibitors and moderate CYP3A4 inhibitors (eg, abiraterone acetate, diltiazem, dronedarone, erythromycin, verapamil) unless benefit outweighs potential bleeding risk [7].
- hepatic impairment, moderate or severe (Child-Pugh B or C) or any hepatic disease associated with coagulopathy: Avoid use [5]
- geriatrics: No adjustment necessary [8]

Print

의약품 안전성 정보 제공



- 의약품 안전성과 관련된 다양한 정보 제공

Home Drug Interactions IV Compatibility Drug ID Drug Comparison CareNotes® NeoFax® / Pediatrics Other Tools ▼

Routes: Oral

Quick Answers In-Depth Answers All Results

Dosing/Administration
Adult Dosing
Pediatric Dosing
FDA Uses
Non-FDA Uses
Dose Adjustments
Administration
Comparative Efficacy
Place In Therapy

Medication Safety
Contraindications
Precautions
Adverse Effects
Black Box Warning
REMS
Drug Interactions (single)
IV Compatibility (single)
Pregnancy & Lactation
Monitoring
Do Not Confuse

Medication Safety
Black Box Warning
See ["In-Depth Answers"](#) for detailed results.

Oral (Tablet)

- Premature discontinuation of any oral anticoagulant, including rivaroxaban, increases the risk of thrombotic events. To reduce this risk, c anticoagulant if rivaroxaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy. Epidural c long-term or permanent paralysis, have occurred in patients treated with rivaroxaban who are receiving neuraxial anesthesia or undergoi between the administration of rivaroxaban and neuraxial procedures is not known. Factors that can increase the risk of developing these epidural catheters; concomitant use of drugs affecting hemostasis, such as NSAIDs, platelet inhibitors, or other anticoagulants; or history spinal puncture, spinal deformity, or spinal surgery. Monitor patients frequently for neurological impairment. If neurological compromise is Consider risks/benefits before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [11].

- 금기
- 경고
- 부작용
- BBW
- REMS
- 약물 상호작용
- IV compatibility
- 임부&수유부 주의 정보
- 모니터링

환자 복약지도문



- 약물명, 질병명, 증상명, 검사명 등 다양한 키워드로 검색 가능
- 약물명 검색 시, 단일/복합제가 모두 검색되고 투여경로 및 제형별로 구분되는 정보 제공

The screenshot shows the CareNotes search interface. At the top, there is a navigation bar with the CareNotes logo and the text 'KIMS CO. LTD'. Below this is a menu with options: Keyword Search, Hot Lists, Care and Condition Titles, Drug Titles, Lab Titles, and Conversion Calculator. A progress bar indicates the current step: 1 Search, 2 Select Titles (highlighted), 3 Select Documents, 4 Customize (optional), and 5 Print. The search results are displayed under the heading 'Your Search: aspirin'. There are three tabs: 'Care and Condition Titles (1 titles)', 'Drug Titles (21 titles)', and 'Lab Titles (0 titles)'. The 'Care and Condition Titles' section shows one result: 'NONPRESCRIPTION MEDICATION OVERDOSE IN CHILDREN (ASPIRIN POISONING)'. The 'Drug Titles' section shows 21 results, including various formulations of Aspirin such as 'Acetaminophen/Aspirin/Caffeine/Salicylamide (Oral) (Tablet)', 'Acetaminophen (Oral) (Capsule, Capsule, Liquid Filled, Liquid, Powder, Tablet, Tablet, Chewable, Tablet, Disintegrating, Tablet, Effervescent, Tablet, Extended Release)', 'Acetaminophen (Rectal) (Suppository)', 'Analgesic/Decongestant (Oral) (Tablet, Packet, Tablet, Chewable, Tablet, Effervescent, Tablet, Capsule, Capsule, Liquid Filled, Liquid, Powder)', 'Antihistamine/Acetaminophen (Oral) (Capsule, Tablet, Packet, Liquid)', 'Aspirin/Caffeine/Dihydrocodeine (Oral) (Capsule)', 'Aspirin/Caffeine (Oral) (Tablet, Powder, Tablet, Effervescent)', 'Aspirin/Citric Acid/Sodium Bicarbonate (Oral) (Tablet, Effervescent, Tablet)', 'Aspirin/Codeine (Oral) (Tablet)', 'Aspirin/Dipyridamole (Oral) (Capsule, Capsule, Extended Release)', 'Aspirin (Oral) (Tablet, Tablet, Chewable, Tablet, Enteric Coated, Tablet, Effervescent, Tablet, Delayed Release, Capsule, Delayed Release, Gum)', and 'Aspirin (Rectal) (Suppository)'. Each result includes a checkbox and a magnifying glass icon.

- 질병명 검색 시, 검색 키워드와 관련된 모든 질병, 증상, 생활습관 개선 사항, 약제 사용법 등의 정보 도출
- 문서 종류를 일반적 복약정보, 입원환자용, 퇴원환자용, ER환자용으로 나누어 제공

Your Search: asthma

Go To: [Care and Condition Titles \(19 titles\)](#) | [Drug Titles \(1 titles\)](#) | [Lab Titles \(0 titles\)](#)

Care and Condition Titles: (19 titles)

- ALLERGIES (ALLERGIC ASTHMA)
- ALLERGIES, AMBULATORY CARE (ALLERGIC ASTHMA)
- ASTHMA (ASTHMATIC)
- ASTHMA, AMBULATORY CARE (ASTHMATIC)
- ASTHMA IN CHILDREN (ASTHMATIC)
- ASTHMA IN CHILDREN, AMBULATORY CARE (ASTHMATIC)
- BRONCHOSPASM (ACUTE ASTHMA)
- CHRONIC OBSTRUCTIVE PULMONARY DISEASE (ASTHMATIC BRONCHITIS, CHRONIC)
- COPD, AMBULATORY CARE (ASTHMATIC BRONCHITIS, CHRONIC)
- COPD EXACERBATION, AMBULATORY CARE (ASTHMATIC BRONCHITIS, CHRONIC)
- EXERCISE-INDUCED ASTHMA
- EXERCISE-INDUCED ASTHMA, AMBULATORY CARE
- EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN (CHILDHOOD ASTHMA)
- HOW TO USE A NEBULIZER (ACUTE ASTHMA)
- HOW YOUR LUNGS WORK (DETERGENT ASTHMA)
- MODERATE AND SEVERE PERSISTENT ASTHMA
- MODERATE AND SEVERE PERSISTENT ASTHMA, AMBULATORY CARE
- REACTIVE AIRWAYS DISEASE (ASTHMA)
- WHEEZING (ASTHMA)

Document Type	✓ Languages
General Information	<input type="checkbox"/> English <input type="checkbox"/> Spanish
Inpatient Care	<input type="checkbox"/> English <input type="checkbox"/> Spanish
Discharge Care	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Arabic <input type="checkbox"/> Chinese (Simpli... <input type="checkbox"/> Chinese (Tradit... <input type="checkbox"/> French (Canadia... <input type="checkbox"/> German <input type="checkbox"/> Italian <input type="checkbox"/> Japanese <input type="checkbox"/> Korean <input type="checkbox"/> Polish <input type="checkbox"/> Portuguese (Bra... <input type="checkbox"/> Russian <input type="checkbox"/> Turkish <input type="checkbox"/> Vietnamese
AfterCare(R) Instructions(ER/ED)	<input type="checkbox"/> English <input type="checkbox"/> Spanish

Add to Pr


약물 독성 정보



- 약물 독성정보의 경우, 'Clinical Effects' 'Range of Toxicity' 'Treatment' 3가지 내용으로 상세하게 제공

TRUVEN HEALTH ANALYTICS
MICROMEDEX® SOLUTIONS

Home	Drug Interactions	IV Compatibility
Monitoring		
Do Not Confuse		
Mechanism of Action		
Pharmacokinetics		
Patient Education		
Medication Counseling		
Patient Handouts		
Toxicology		
Clinical Effects		
Range of Toxicity		
Treatment		
About		
How Supplied		
Drug Properties		
Storage & Stability		
Trade Names		
Regulatory Status		
References		



TRUVEN HEALTH ANALYTICS
MICROMEDEX® SOLUTIONS

My Subscription | Rivaroxaban

Home Drug Interactions IV Compatibility Drug ID Drug Comparison CareNotes® NeoFax® / Pediatrics Other Tools ▾

Rivaroxaban

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)
Routes: Oral

Quick Answers In-Depth Answers All Results

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS
- Drug Interactions (single)
- IV Compatibility (single)

Toxicology Treatment

RIVAROXABAN AND RELATED AGENTS

- Support: MILD TO MODERATE TOXICITY: Treatment is symptomatic and supportive. Monitor for evidence of bleeding. MANAGEMENT OF SEVERE TOXICITY: Treatment is symptomatic and supportive. Transfusion of packed red cells and fresh frozen plasma may be indicated in patients with severe bleeding.
- Decontamination: PREHOSPITAL: Consider activated charcoal after a recent potentially toxic ingestion and if the patient is able to maintain their airway or if the airway is protected. HOSPITAL: Consider activated charcoal after a recent potentially toxic ingestion and if the patient is able to maintain their airway or if the airway is protected.
- Airway management: Assess airway; endotracheal intubation may be required in patients with intracranial bleeding or severe hemoptysis or upper GI bleeding.
- Antidote: None.
- Monitoring of patient: Monitor for evidence of bleeding (eg, venous access sites, urinary, gastrointestinal, vaginal). Monitor serial hemoglobin and hematocrit in patients with suspected bleeding. Monitor CBC with platelet count, vital signs, and liver enzymes in symptomatic patients. Prothrombin time (PT) and aPTT are relatively insensitive in measuring the activity of rivaroxaban at therapeutic doses, but may be prolonged after overdose. Plasma anti-factor Xa concentrations can be measured, but results are generally not available rapidly enough to use this to guide therapy.
- Enhanced elimination procedure: Rivaroxaban is highly protein bound and dialysis is not expected to be useful after overdose.
- Patient disposition: HOME MANAGEMENT: Patients that unintentionally ingest one or two doses of oral rivaroxaban may be observed at home. OBSERVATION CRITERIA: Intentional overdoses and patients with bleeding complications should be referred to a healthcare facility. Patients with minor bleeding complications can be observed until the bleeding is controlled. ADMISSION CRITERIA: Patients with more than minor bleeding complications should be admitted for serial hemoglobin and hematocrit monitoring. CONSULT CRITERIA: If the patient still requires anticoagulation, hematology should be consulted for anticoagulation guidance. A toxicologist or poison center should be consulted in patients with severe toxicity.

Print

3. Micromedex Tools

- 약물 상호작용 도구
- Trissel's IV Compatibility
- 약물 비교 도구
- 환자 복약 정보
- 계산기

Micromedex Tools 정보

- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax / Pediatrics
- RED BOOK
- Tox & Drug Product Lookup
- Formulary
- Calculators

약물 상호작용 도구



- 여러 약물에 대한 상호작용 정보를 한 번에 분석할 수 있는 도구
- 약물 상호작용 분석 시 환자 알러지 정보 추가 가능
- 상호작용에 대한 심각도와 문헌보고도, 요약정보, 상세정보 제공
- 약물-약물 상호작용 뿐만 아니라 첨가제, 알러지, 음식, 술, 검사, 담배, 임부, 수유부에 관한 9가지의 상호작용 정보 제공

Drug Interaction Results

← Modify Interactions

Refine by: Drugs: All Severity: All Documentation: All Type: All

Jump To: DRUG-DRUG (1) | Ingredient Duplication (0) | ALLERGY (1) | FOOD (3) | ETHANOL (0) | LAB (2) | TOBACCO (0) | PREGNANCY (3) | LACTATION (3)

Drug-Drug Interactions (1)

Drugs:	Severity:	Documentation:	Summary:
CLARITHROMYCIN – SIMVASTATIN	Contraindicated	Good	Concurrent use may increase the risk of adverse effects.

Ingredient Duplication (None found)

Drug-ALLERGY Interactions (1)

Drugs:	Severity:	Documentation:	Summary:
--------	-----------	----------------	----------



ADD ALLERGIES.

Type the allergy in the search field. Select the allergy and click the (Add) button. Click UPDATE to add your selection(s) to the "Drugs to Check" list in Drug Interactions.

Enter allergy:

peanut

Matching allergies: (2)

PEANUT OIL

PEANUTS

Allergies to check:

PENICILLIN G

Cancel

Update

Home Drug Interactions IV Compatibility Drug ID Drug Comparison CareNotes® NeoFax® / Pediatrics Other Tools ▾

Drug Interaction Results

Refine by: Drugs: All

Jump To: DRUG-DRUG (1) | Ingredient Duplication (0) | ALLERGY (1)

Drug-Drug Interactions (1)

Drugs:

CLARITHROMYCIN – SIMVASTATIN

Ingredient Duplication (None found)

Drug-ALLERGY Interactions (1)

Drugs:

PENICILLIN G SODIUM – PENICILLIN G

INTERACTION DETAIL

Warning:
Concurrent use of CLARITHROMYCIN and SIMVASTATIN may result in an increased risk of myopathy or rhabdomyolysis.

Clinical Management:
The concurrent use of clarithromycin and simvastatin is contraindicated. If clarithromycin therapy is necessary, suspend simvastatin during the course of treatment (Prod Info ZOCOR® oral tablets, 2011).

Onset:
Not Specified

Severity:
Contraindicated

Documentation:
Good

Probable Mechanism:

PRINT CLOSE

Drug Interactions

Type the drug name (brand or generic) in the search field. Select

Enter search term:

Matching drug names: (12)

- Penicillin (Penicillin G Potassium)
- Penicillin (Penicillin V Potassium)
- Penicillin G Benzathine
- Penicillin G Benzathine/Penicillin G P...
- Penicillin G Potassium
- Penicillin G Potassium-Sodium Chloride
- Penicillin G Potassium/Sodium Chloride
- Penicillin G Procaine
- Penicillin G Sodium**
- Penicillin V
- Penicillin V Potassium
- Penicillin VK

Trissel's IV Compatibility



- 여러 약물을 정맥 주사할 때의 호환성 정보 제공
- 한 가지 약물 검색 시, Solution, Y-Site, Admixture, Syringe, TPN/TNA 5가지 정보 제공
- 여러 약물을 동시 분석 시, Y-Site, Admixture, Syringe 3가지 정보 제공
- 상세정보에서는 연구방법(연구기간, 저장상태 등)을 명시하고 물리적/화학적 호환성 정보를 종합적으로 제시

IV 호환성 결과 < 호환성 수정

Selected Drug: [Warfarin sodium](#)

All Drugs (3)
 모두 체크 | 모두 선택 해제

[Gentamicin sulfate](#)
 [Vancomycin hydrochloride](#)
 [Warfarin sodium](#)

취소 업데이트

Solution Y-Site Admixture Syringe TPN/TNA

Key :

호환성: All

Y-Site Test Detail	Rating
- Amikacin sulfate	호환됨
- Aminophylline	비호환
- Ammonium chloride	주의, 가변
- Ascorbic acid injection	호환됨
- Bivalirudin	호환됨
- Bretylium tosylate	비호환
- Cangrelor	호환됨
- Cefazolin sodium	호환됨

IV 호환성 결과 < 호환성 수정

All Drugs (3)

모두 체크 | 모두 선택 해제

Gentamicin sulfate

Vancomycin hydrochloride

Warfarin sodium

Tip: To see additional information on IV Solutions and TPN/TNA compatibility, select a single drug from the list and choose Update.

Y-Site

Y-Site Test Detail	Rating
Gentamicin sulfate - Vancomycin hydrochloride	호환됨
Gentamicin sulfate - Warfarin sodium	비호환
Vancomycin hydrochloride - Warfarin sodium	주의: 가변

IV COMPATIBILITY DETAIL

약물 1	약물 2	상태	정보	검사 매개변수
Gentamicin sulfate 6.4mg/mL in D5W-Dextrose 5% American Pharmaceutical Partners	Vancomycin hydrochloride 20mg/mL in D5W-Dextrose 5% Abbott Laboratories	 호환됨	물리적 호환성: Physically compatible. No changes in measured haze or turbidity, particulates, or color were found. 보관: Ambient room temperature near 23 °C exposed to normal fluorescent light.	참조: 8840 연구 기간: 4 hours. 방법: Visual observation and electronic assessment. 용기: Simulated Y-site administration using glass test tubes.
Gentamicin sulfate 6.4mg/mL in Dextrose 5% in sodium chloride 0.9% American Pharmaceutical Partners	Vancomycin hydrochloride 20mg/mL in Dextrose 5% in sodium chloride 0.9% Abbott Laboratories	 호환됨	물리적 호환성: Physically compatible. No changes in measured haze or turbidity, particulates, or color were found. 보관: Ambient room temperature near 23 °C exposed to normal fluorescent light.	참조: 8840 연구 기간: 4 hours. 방법: Visual observation and electronic assessment. 용기: Simulated Y-site administration using glass test tubes.
약물 1	약물 2	상태	정보	검사 매개변수
Gentamicin sulfate	Vancomycin		물리적 호환성: Physically	참조: 8840

PRINT CLOSE

약물 비교 도구

- 약물을 한 눈에 비교하기 위한 '약물 비교 도구(Drug Comparison)' 제공
- 요약 정보를 병렬적으로 비교 가능



Drug Comparison

Type the drug name (brand or generic) in the search field. Select the drug and click the  (Add) button.

Enter search term:

Matching drug names: (6)

- Naproxen
- Naproxen Na
- Naproxen Na/Sumatriptan Succinate
- Naproxen Sodium
- Naproxen Sodium/Sumatriptan Succinate
- Naproxen/Esomeprazole magnesium

Drug Comparison Results

재검색

열에 표시 1

Ibuprofen

열에 표시 2

Naproxen

약대비교

인쇄

이동 위치: [+ 페이지 상단](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single\)](#) | [Adverse Effects](#) | [Name Info](#) | [Mechanism of Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

Mechanism of Action/Pharmacokinetics

Mechanism of Action

DRUGDEX의 자세한 정보 보기 ▶

- Ibuprofen is a nonsteroidal antiinflammatory drug (NSAID) that exhibits analgesic and antipyretic activities by inhibiting prostaglandin synthesis [3][14]

Pharmacokinetics

DRUGDEX의 자세한 정보 보기 ▶

Absorption

- T_{max}, oral: 1 to 2 hr [14]
- Effects of food: T_{max} increased from 1.34 to 1.96 hours with single dose [15]

Distribution

- V_d: 0.11 to 0.18 L/kg [16]; (Tech Info Motrin(R), 1981)
- Protein binding, primarily albumin; 99% [16]; (Davies, 1975)[17][18]

Metabolism

- Liver; rapidly metabolized [11]

Mechanism of Action/Pharmacokinetics

Mechanism of Action

DRUGDEX의 자세한 정보 보기 ▶

- Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic activities. Its mechanism of action is unknown but it is thought to be related to inhibition of prostaglandin synthetase [9].

Pharmacokinetics

DRUGDEX의 자세한 정보 보기 ▶

Absorption

- Oral, tablet: time to peak concentration, 2 h to 4 h [9]
- Oral, suspension: time to peak concentration, 1 h to 4 h [9]
- Oral, delayed release tablet: time to peak concentration, 4 h to 6 h (2 h to 12 h)
- Bioavailability: 95% [9]
- Effect of food: increases T_{max} to 12 h (range 4 h to 24 h) [9]

Distribution

- V_d: 0.16 L/kg [9]
- Protein binding: greater than 99% [9]

환자 복약 정보

- 환자 복약 지도를 위한 '환자 복약 정보(CareNotes®)' 제공

CareNotes® : MICROMEDEX SALES DEMO MICROMEDEX GATEWAY | LOGOUT | Page Help

Keyword Search | Hot Lists | Care and Condition Titles | Drug Titles | Lab Titles | Print List | Conversion Calculator

Location: St. Ag

Send CareNotes®
Search Path: Keyword Search
CELLULITIS

View: English

您应了解的信息:
哮喘是一种使呼吸困难的肺部疾病。慢性炎症和对诱发因素的反应会使肺部气道变窄。如果不加以治疗,哮喘会危及生命。


回家后:
药物:

- 药物可缓解炎症,打开气道,使呼吸更顺畅。哮喘药物可以吸入,作为药片服用,或者注射。短期药物可以快速缓解症状。长期药物用于预防未来发作。您可能也需要帮助控制过敏的药物。
- 服药请遵医嘱。如果觉得药物无效或有副作用,请联系您的主要医护人员(PHP)。如对任何药物过敏,请告知。请保留一份所服用药物、维生素和中草药的药单。注明服用的药量以及服药

Follow up with
Elevate your ar
Wear pressure
Self-care:
Do not sh
Clean exercise equipment: Clean the exercise equipment you use with germ-killing cleaner before and after you use it.
Clean your wound: Wash it regularly with soap and water. Watch carefully for signs of infection.
Take care of your skin: Use lotion to prevent dry, cracked skin.

Available in 15 languages

哮喘



气管 肺
患有气喘的细支气管
正常的细支气管
ADAM

Calculators

View: [by category](#) | [by alphabetical list](#) ▶

ANTIDOTE DOSING AND NOMOGRAMS

- Alcohols/Ethylene Glycol Blood Level
- Ethanol - IV Dosing for Methanol/Ethylene Glycol Overdose
- NAC Dosing for Acetaminophen Overdose
- Toxicity Nomograms

LABORATORY VALUES

- Anion Gap Calculator
- Creatinine Clearance Calculator**
- Phenytoin Level Adjustment Calculator

DOSING TOOLS

- ACLS/PALS Guidelines**
- Dobutamine Dosing Calculator
- Dopamine Dosing Calculator
- Epinephrine Dosing Calculator - Adult
- Epinephrine Dosing Calculator - Pediatric
- Heparin Dosing Calculator
- IV Rate Calculator**
- Nitroglycerin Dosing Calculator
- Nitroprusside Dosing Calculator
- Norepinephrine Dosing Calculator - Adult
- Norepinephrine Dosing Calculator - Pediatric

CLINICAL CALCULATORS

- Alveolar-Arterial Oxygen Gradient

MEASUREMENT CALCULATORS

- Body Mass Index Calculator**
- BSA and Lean/Ideal Body Weight Calculator**
- Metric Conversions Calculator
- SIU Conversion Calculator

Creatinine Clearance Calculator

[CLOSE]

Actual Total Body Weight: kg lb
Body Length: cm in
Age: Years Months
Gender: M F
Serum Creatinine: mg/dL

Method:

Estimate from serum creatinine
 Calculate from 24-hour urine collection

[Calculator Help](#)

4. Micromedex Search Skill

- 검색 방법
- 자동 완성 기능
- 유사 검색어 찾기 기능
- 사용자 중심의 UI
- 업데이트
- Pub-med 링크

검색 방법



- 통합 검색창에서 특정 DB(Drug, Disease, Toxicology)로 제한하여 검색가능
- 기본적으로 제품명(ex. Xarelto), 성분명(ex. Rivaroxaban), 약물 계열(ex. Factor Xa Inhibitor), 질병명(ex. Deep venous thrombosis)으로 검색 가능
- 구글링 방식을 채택하여 문장 검색 가능(ex. Drugs that treat breast cancer)
- BBW, REMS 등 자주 사용하는 특정 검색어도 검색 가능

The screenshot shows the Micromedex website interface. At the top, there is a navigation bar with links: Home, Drug Interactions, IV Compatibility, Drug ID, Drug Comparison, CareNotes®, NeoFax® / Pediatrics, and Other Tools. Below this is a large blue search area with a search bar containing the text "Search Micromedex" and a magnifying glass icon. Above the search bar are tabs for "All", "Drug", "Disease", and "Toxicology". Below the search bar, there are three main sections: "Latest News" (green header), "Support & Training" (blue header), and "Resources" (purple header). The "Resources" section contains a table with search terms and descriptions.

Search Term/Phrase	Description
2015	Returns the Drug Consults, <i>New Drug Approvals - 2015 Micromedex News</i> and <i>Childhood Immunization Schedule - United States 2015</i> . The immunization schedule is based on recommendations from the U.S. Centers for Disease Control and Prevention.*
Abbreviations	Returns the Drug Consult, <i>Abbreviations</i> , which provides definitions for abbreviations used commonly throughout Micromedex content.*
BBW (or Black Box) ✕	Returns a list of drugs that carry a black-box warning. Selecting a drug link opens the black-box warning content.
Causes of [Disease/Condition]	Returns links to the Disease Summary Dashboards, and to the Medical History or Etiology/ Pathophysiology sections in disease reviews.* Example: <i>causes of anemia</i>
Chemotherapy	Returns various Drug Consults, such as the <i>Chemotherapy Acronyms and Dosing</i> , <i>Chemotherapy Dosing in Obese Adults</i> , <i>Chemotherapy and Radiotherapy Protectants - ASCO Clinical Practice Guidelines</i> , and <i>Chemotherapy and Radiotherapy Treatment Guidelines for Nausea and Vomiting</i> .*
Clinical Approach To	Click on the Toxicology Results link to see toxin-induced disease states (hyperthermia, hypotension, metabolic acidosis, or tachyarrhythmia).*
Comparative Table ✕ [Condition Name]	Returns lists of comparative drug class tables. Typing a condition opens search suggestions that land in the disease dashboard. Or you can execute the <i>drugs that cause</i> and <i>drugs that treat</i> searches (see below for details).
Confused Drug Names ✕	Presents a list of commonly confused drug names, including look-alike and sound-alike name pairs.
Consults (or Drug Consults) ✕	Displays an alphabetical list of Drug Consults, which are evidence-based documents covering a broad range of topics, including comparative drug tables, clinical guideline summaries, drug class-related adverse effects discussions, chemotherapy regimen acronyms, and other therapeutic overviews spanning multiple drugs or classes.

자동 완성 기능



Home Drug Interactions IV Compatibility Drug ID Drug Comparison CareNotes® NeoFax® / Pediatrics Other Tools ▾

All Drug Disease Toxicology

Search Drug, Disease, Toxicology, and more

Warfarin

- Warfarin
- Warfarin Dosing
- Warfarin Interactions
- Warfarin Adverse Effects
- Warfarin Indications

Warfarin Measurement
Warfarin Monitoring Status
Warfarin Necrosis

es

Latest News

- Gastric Cancer Drug Approved
- Decline in Adult Diabetes-Related Com...
- Sublingual Ragweed Pollen Allergy Ext...
- New Oral Immunotherapy Approved
- New Type 2 Diabetes Drug Approved

Read Top News ▶

- Training & Tutorials
- User Guide
- Citing Micromedex

Support Request ▶

- Do not Confuse
- Drug Class
- Drug Consults
- REMS

Download Mobile Apps

유사 검색어 찾기 기능



A screenshot of a web application's search interface. At the top, there is a horizontal navigation bar with several menu items: Home, Drug Interactions, IV Compatibility, Drug ID, Drug Comparison, CareNotes®, NeoFax® / Pediatrics, and Other Tools. Below this is a large blue search area. In the center, there is a white search input field containing the text "zarelto". To the right of the input field is a magnifying glass icon. Below the input field, a dropdown menu is visible, showing the corrected text "xarelto". A red arrow points from a text box to the "xarelto" suggestion in the dropdown.

Intelligent searching with in-line spelling corrections

사용자 중심의 UI 제공



- 좌측 내비게이션을 통해 빠른 카테고리 이동 가능
- 우측 DB 연결창을 통해 해당 성분 정보 페이지에서 관련 있는 DB로 연결

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes®	NeoFax® / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	------------	----------------------	---------------

Rivaroxaban

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: [Oral](#)

Quick Answers	In-Depth Answers	All Results
---------------	------------------	-------------

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS
- Drug Interactions (single)

Dosing/Administration

Adult Dosing

See ["In-Depth Answers"](#) for detailed results.

- missed dose: Administer as soon as possible on the same day; if necessary, patients taking 15 mg twice daily may take two 15-mg tablets at once to ensure administration of 30 mg/day [1].
- surgical and other procedures: If required, discontinue rivaroxaban at least 24 hours prior to procedure and restart after the procedure as soon as adequate hemostasis is established; weigh risk of increased bleeding against the urgency of the procedure [2].
- switching from warfarin to rivaroxaban, discontinue warfarin and initiate rivaroxaban when INR is less than 3 [2]
- switching from another anticoagulant other than warfarin to rivaroxaban, initiate rivaroxaban 0 to 2 hours before the next scheduled evening dose and discontinue the other anticoagulant [2]
- switching from unfractionated heparin continuous infusion to rivaroxaban, discontinue infusion and initiate rivaroxaban at the same time [2]
- switching from rivaroxaban to warfarin, discontinue rivaroxaban and initiate a parenteral anticoagulant and warfarin at the time when the next rivaroxaban dose would have been administered (rivaroxaban affects INR) [2]
- switching from rivaroxaban to a rapid-onset anticoagulant, discontinue rivaroxaban and initiate the first dose of the other anticoagulant (oral or parenteral) at the time when the next rivaroxaban dose would have been administered [2]
- Acute coronary syndrome, Recent - Cardiovascular event risk; Prophylaxis: 2.5 mg to 5 mg ORALLY twice daily (study dosing) [3]
- Acute coronary syndrome, Recent - Cardiovascular event risk; Prophylaxis: Patients with coronary stents: 2.5 mg ORALLY twice daily (study dose) [4]
- Arthroplasty of knee - Postoperative deep vein thrombosis: Prophylaxis: 10 mg ORALLY once daily beginning at least 6 to 10 hours after surgery and continued for 12 days [5]



Related Results

[Alternative Medicine](#)
[Disease](#)
[Toxicology](#)

[Consumer Drug Information](#)
[Drug Consults](#)
[eMC SmPC \(UK\)](#)
[Index Nominum](#)
[IT- Dialogo Sui Farmaci](#)
[Martindale](#)
[PDR®](#)
[Product Lookup - Martindale](#)
[Product Lookup - RED Book Online](#)
[Product Lookup - Tox & Drug](#)

업데이트 현황



- 매일 중요 업데이트
- 매주 정기 업데이트

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes®	NeoFax® / Pediatrics	Other Tools ▼
------	-------------------	------------------	---------	-----------------	------------	----------------------	---------------

Glimepiride

Drug Classes: [2nd Generation Sulfonylurea](#) | [Antidiabetic](#) | [All](#)

Routes: [Oral](#)

Quick Answers	In-Depth Answers	All Results
---------------	------------------	-------------

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS
- Drug Interactions (single)
- IV Compatibility (single)
- Pregnancy & Lactation

About

References

See ['In-Depth Answers'](#) for detailed results.

1. Institute for Safe Medication Practices: ISMP's list of confused drug names. Institute for Safe Medication Practices. Huntingdon Valley, PA. 2005. Available at: <http://ismp.org/T...>
2. Thompson CA: USP says thousands of drug names look or sound alike. Am J Health Syst Pharm 2008; 65(5):386-388. PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...> PubMed Article: <http://www.ncbi.nlm.nih.gov/...>
3. Product Information: AMARYL(R) oral tablets, glimepiride oral tablets. sanofi-aventis U.S. LLC (Per FDA), Bridgewater, NJ, 2012.
4. Product Information: AMARYL(R) oral tablets, glimepiride oral tablets . Sanofi-Aventis U.S. LLC (per FDA), Bridgewater, NJ, 2013.
5. American Diabetes Association : Standards of medical care in diabetes--2014. Diabetes Care 2014; 37 Suppl 1:S14-S80. PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...> PubMed Article: <http://www.ncbi.nlm.nih.gov/...>
6. Isselbacher KJ, Braunwald E, Wilson JD, et al (Eds): Harrison's principles of internal medicine, 13th. McGraw-Hill, Inc, New York, NY, 1994.
7. Product Information: Amaryl. Hoechst Marion Roussel, US, 95.
8. Therapeutic Goods Administration: Prescribing medicines in pregnancy database. Therapeutic Goods Administration. Woden, Australian Capital Territory. URL: <http://www.tga.gov...> . As accessed 2011-06-20.

Last Modified: April 27, 2015

Home | Drug Interactions | IV Compatibility | Drug ID | Drug Comparison | CareNotes® | NeoFax® / Pediatrics | Other Tools ▾

Rivaroxaban

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)
Routes: [Oral](#)

[Quick Answers](#) | [In-Depth Answers](#) | [All Results](#)

Dosing/Administration

Adult Dosing

See 'In-Depth Answers' for detailed results.

- missed dose: Administer as soon as possible on the same day; if necessary, [1].
- surgical and other procedures: If required, discontinue rivaroxaban at least 24 hours before surgery to weigh risk of increased bleeding against the urgency of the procedure [2].
- switching from warfarin to rivaroxaban, discontinue warfarin and initiate rivaroxaban at the time when the next rivaroxaban dose would have been administered [2].
- switching from another anticoagulant other than warfarin to rivaroxaban, initiate rivaroxaban 0 to 2 hours before the next scheduled evening dose and discontinue the other anticoagulant [2].
- switching from unfractionated heparin continuous infusion to rivaroxaban, discontinue infusion and initiate rivaroxaban at the same time [2].
- switching from rivaroxaban to warfarin, discontinue rivaroxaban and initiate a parenteral anticoagulant and warfarin at the time when the next rivaroxaban dose would have been administered (rivaroxaban affects INR) [2].
- switching from rivaroxaban to a rapid-onset anticoagulant, discontinue rivaroxaban and initiate the first dose of the other anticoagulant (oral or parenteral) at the time when the next rivaroxaban dose would have been administered [2].
- Acute coronary syndrome, Recent - Cardiovascular event risk; Prophylaxis: 2.5 mg to 5 mg ORALLY twice daily (study dosing) [3].
- Acute coronary syndrome, Recent - Cardiovascular event risk; Prophylaxis: Patients with coronary stents: 2.5 mg ORALLY twice daily (study dose) [4].
- Arthroplasty of knee - Postoperative deep vein thrombosis; Prophylaxis: 10 mg ORALLY once daily beginning at least 6 to 10 hours after surgery and continued for 12 days [5].

References

[4] Gibson CM, Chakrabarti AK, Mega J, et al: Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. *J Am Coll Cardiol* 2013; 62(4):286-290.

PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>

PubMed Article: <http://www.ncbi.nlm.nih.gov/...>

닫기

Related Results

- [Alternative Medicine](#)
- [Disease](#)
- [Toxicology](#)
- [Consumer Drug Information](#)
- [Drug Consults](#)
- [eMC SmPC \(UK\)](#)
- [Index Nominum](#)
- [IT- Dialogo Sui Farmaci](#)
- [Martindale](#)
- [PDR®](#)
- [Product Lookup - Martindale](#)
- [Product Lookup - RED Book Online](#)
- [Product Lookup - Tox & Drug](#)

5. Micromedex 활용

- 병원에서 Micromedex 활용
- 학교에서 Micromedex 활용
- 실험 연구에서 Micromedex 활용

병원에서 Micromedex 활용



1) 병원 전체에서 활용 가능

- : 동시이용자수 제한 없이 이용 가능
- : 임상, 약사, 간호사가 모두 활용하는 데이터베이스
- : 환자 진료 시, 가장 빠르게 답변 제공하는 데이터베이스

2) 소아과, 산부인과, 응급의학과 등 다양한 진료과에서 활용 가능

- : 소아, 노인, 임부 등 특정 환자에 관한 상세 정보를 제공하는 데이터베이스 제공
- : 환자의 특성에 맞는 용량/용법, 부작용 정보 제공

3) Point Of Care Tool 및 EBM 정보원으로 활용

- : 가장 빠른 신약 정보 업데이트
- : Reference 요약으로 근거 제공
- : 환자 진료 시 활용할 수 있는 근거중심 약물정보 데이터베이스

4) 다양한 복약지도문 활용 가능

- : 외국인 환자를 위한 복약지도문 제공 가능
- : 신약에 대한 복약지도문 업데이트
- : 복약지도문 자체 제작 시 활용할 수 있는 정보 제공
- : 의약품 이미지 및 질병에 관한 이미지 제공

5) 신약선정 시 활용

- : 약물 비교 테이블 쉽게 제작 가능
- : 약물비교평론에서 약물간 비교효능에 관한 문헌 리뷰 제공함.
- : 우리 병원에서 신약 선정 시, 유용하게 활용

1) 학생들 강의용으로 사용

- : 필수 의약품정보원 모두 제공됨 (Lexicomp/ Martindale /AHFS DI / Facts and Comparisons)
- : 학생들에게 알맞은 용도의 정보 제공
- : 약물 정보 외에 Interaction Checking, IV Compatibility, 계산기, 복약지도문 등 제공
- : 약물치료학 등의 강의에서 활용
- : 복약지도문 제작 실습 시 정보원으로 활용

2) 학생들 실습용으로 사용

- : 실습지에서 활용할 수 있는 데이터베이스
- : 모바일 어플리케이션 구독 시, 모바일 설치하여 실습지에서 활용
- : 현재 16개 약학대학에서 실습용 정보원으로 활용하고 있음

실험 연구에서 Micromedex 활용



- 실험 및 연구정보인 Lab Test 데이터베이스도 제공
- 학교에서 연구용 및 학생들이 현재 이뤄지고 있는 연구에 대한 정보원으로 활용 가능



42 results found for: "Alanine aminotransferase measurement"

All Results

- Filter by
- All (42)
 - Drug (5)
 - Disease (29)
 - Lab (8)

1-8 of 8 Results for "Alanine aminotransferase measurement"

[Alanine aminotransferase measurement](#)
Laboratory Test: Detailed evidence-based information (Lab Advisor™)
...pyruvate transaminase measurement [GPT measurement](#) [SGPT measurement](#)
Document section:
- [Synonyms](#) ▶

[Amylase/creatinine clearance ratio measurement](#)
Laboratory Test: Detailed evidence-based information (Lab Advisor™)

Navigation bar: Home, Drug Interactions, IV Compatibility, Drug ID, Drug Comparison, CareNotes®, NeoFax® / Pediatrics, Other Tools

GENERAL INFORMATION

Synonyms: Alanine aminotransferase measurement
Reference Range: 실험실 자문™ ⓘ
Test Definition: 실험실 자문™ ⓘ

INDICATIONS

ABNORMAL RESULTS

DRUG/LAB INTERACTIONS

- [HYDROXOCOBALAMIN](#) - artificially reduced serum alanine aminotransferase (ALT) levels
- [METRONIDAZOLE](#) - interference in serum alanine aminotransferase measurement
- [TINIDAZOLE](#) - interference in serum alanine aminotransferase measurement

COLLECTION / STORAGE INFORMATION

TEST METHODOLOGY

LOINC CODES

COMMON PANELS

RELATED INFORMATION

REFERENCES

6. Mobile Micromedex

- Mobile User Guide

Mobile User Guide




- 현재 Micromedex를 구독하고 계신 경우, 추가 비용 없이 이용하실 수 있습니다.



[앱 다운로드 및 사용방법]

- Apple Store나 Google Play Store에서 'Micromedex'를 키워드로 검색해주세요.
- 'Micromedex'를 입력하여 앱을 다운로드 받습니다.
- 앱을 실행하면 인증번호를 입력하게 되어있습니다.
- Micromedex 웹 홈페이지 오른쪽 하단 'Download Mobile Apps'에 들어가세요



Mobile User Guide



Micromedex® Drug Interactions

- The Micromedex Drug Interactions app for Apple, and Android devices is available for FREE for Micromedex customers.
- You can access these apps via the iTunes® App Store (Apple devices) or Google Play® (Android devices).
- You can activate the app by following the simple instructions below.

Simple instructions for installation:

Step 1: Visit the iTunes App Store (Apple devices), or Google Play Store (Android devices) and search for "Micromedex."

Step 2: From all the Micromedex app results, select Micromedex Drug Interactions. You may be prompted to enter your Apple or Google ID.

Step 3: The app should download directly to your device. (If you visited the iTunes App Store on your PC rather than your device, you may have to sync your device to iTunes on your PC, in order to load the app onto your device.)

Step 4: Open the app on your device. Enter the password [REDACTED] to begin using Micromedex Drug Interactions. The password is case-sensitive. Please enter it exactly as it appears here.

- 'Step 4'에 기관별 인증번호를 확인하실 수 있습니다. 확인된 6자리의 영문과 숫자조합의 인증번호를 앱에 입력해 주세요.
- 애플 휴대폰을 이용하고 계신 경우, 기존과 동일한 방식으로 iTunes App Store에서 아래와 같은 3가지 앱을 다운로드 받아 이용하실 수 있습니다.
 - Free Micromedex Drug Reference
 - Micromedex Drug Interactions
 - Micromedex IV Compatibility
 - Micromedex NeoFax Essentials
 - Micromedex Pediatrics Essentials

Mobile User Guide



Micromedex Solutions Accessible Anytime, Anywhere



7. Appendix

- Micromedex 요약분석
- 국내 기관별 사용 현황

① Micromedex 요약 분석

	Micromedex
Drug summary, detail information	<ul style="list-style-type: none"> - Drug Points 요약 정보제공 - Drugdex 자세한 정보 제공 - 복용정보는 Carenotes 에서 제공 - 전문의료인용 복용지침 clinical teaching guide 제공 - FDA-Labelled indication 정보제공 - Non-FDA Indication 정보 제공
문헌 권장 등급	<ul style="list-style-type: none"> -MICROMEDEX는 엄격한 문헌 평가 정책에 따라 정보를 구축 -문헌보고도, 권장/근거 등급을 제공하여 정확한 의사 결정을 지원
NICE 인증여부	MICROMEDEX는 객관적인 편집과정에 대하여 의약학 DB 중 유일하게 NICE 인증을 받은 정보원임.
Drug monograph 임상연구 자료	-임상연구 자료 제공으로 객관적인 판단 지원,
약물정보양	75-100 페이지/약물 1개
편집위원	<ul style="list-style-type: none"> -90명이상의 내부 편집인력 (경쟁사에 비해 약 7배 이상 큰 규모) -컨텐츠 구축을 위해 전세계 20만 여 종의 참고 문헌 검토

② Micromedex 요약분석

	Micromedex
Drug Interaction	<ul style="list-style-type: none"> - 9가지 drug checker를 제공 - Drug-Allergy를 비롯한 총 9개 분류에 따른 상호작용 제공 <ul style="list-style-type: none"> - Drug-Drug - Ingredient Duplication - Drug-Allergy - Drug-Food - Drug-Ethanol - Drug-Lab - Drug-Tobacco - Drug-Pregnancy - Drug-Lactation - 분류별 상호작용 확인에 용이한 화면구성
IV Compatibility	<ul style="list-style-type: none"> - Trissel's IV Compatibility 정보 제공 - Y-Site / Admixture / Syringe에 해당하는 Compatibility 정보 제공 - Solution과의 Compatibility 확인 가능 - Storage 등 해당 의약품의 특성 제공
Mobile	<ul style="list-style-type: none"> - 모든 기종에 모바일 버전 제공 - 이용자 수에 따른 추가 과금없음
업데이트 주기	<ul style="list-style-type: none"> - 매일 업데이트

Thank You.